Table 3.
Comparison of clinical features of monogenic and nonmonogenic inflammatory bowel disease groups
| Nonmonogenic IBD | Monogenic IBD | P value | |
| Diagnosis | |||
| CD, % | 75.0 | 50.0 | |
| IBD-U, % | 18.2 | 40.0 | |
| UC, % | 6.8 | 10.0 | |
| Abdominal pain, n | 25 | 2 | 0.142 |
| Diarrhea, n | 36 | 8 | 1.000 |
| Bloody stools, n | 26 | 8 | 0.131 |
| Malnutrition, n | 19 | 5 | 0.489 |
| Growth failure, n | 14 | 4 | 0.461 |
| Oral ulcers, n | 3 | 1 | 0.529 |
| Persistent fever, n | 3 | 0 | 1.000 |
| Perianal diseases, n | 9 | 7 | 0.001a |
| Body weight Z-score | -1.54 (-4.69, 2.20) | -2.04 (-3.66, 0.96) | 0.303 |
| Height Z-score | -1.38 (-6.43, 2.51) | -1.76 (-4.92, 0.46) | 0.597 |
| WBC, as a109 | 15.04 ± 1.72 | 12.53 ± 1.72 | 0.382 |
| HGB, in g/L | 103.02 ± 2.57 | 106.67 ± 5.00 | 0.496 |
| PLT, as a1012 | 454.60 ± 28.40 | 421.89 ± 54.97 | 0.632 |
| CRP, in mg/L | 51.16 ± 8.43 | 20.22 ± 2.43 | 0.668 |
| ESR, in mm/h | 29.22 ± 4.70 | 21.00 ± 4.56 | 0.923 |
| ALB, in g/L | 33.80 ± 1.10 | 36.60 ± 1.77 | 0.283 |
| Steroid, n | 36 | 6 | 0.399 |
| Antibiotics, n | 29 | 7 | 0.484 |
| Mesalazine, n | 32 | 2 | 0.009a |
| Immunosuppressants, n | 25 | 8 | 0.075 |
| Nutrition, n | 33 | 5 | 0.425 |
| Infliximab, n | 14 | 4 | 0.461 |
| Surgery, n | 6 | 4 | 0.050 |
| Death, n | 5 | 1 | 0.000a |
a
P < 0.05. IBD: Inflammatory bowel disease.